Systemic therapy for Merkel cell carcinoma: What's on the horizon?

Cancers

Volumn 6, Issue 2, 2014, Pages 1180-1194

  Rabinowits, Guilherme ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Immunotherapy; Merkel cell carcinoma; Merkel cell polyomavirus; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BRENTUXIMAB VEDOTIN; CABOZANTINIB; CISPLATIN; CYTOTOXIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOXORUBICIN; IMATINIB; INTERLEUKIN 2; IPILIMUMAB; KADCYCLA; LORVOTUZUMAB MERTANSINE; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY F16; MPDL 3280A; OBLIMERSEN; OCTREOTIDE; PACLITAXEL; PASIREOTIDE; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLACEBO; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN BCL 2; PROTEIN INHIBITOR; SEPANTRONIUM BROMIDE; STEM CELL FACTOR RECEPTOR; SURVIVIN; TDM 1; TOLL LIKE RECEPTOR AGONIST; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; ANGIOGENESIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; EMULSION; HUMAN; IMMUNOPATHOLOGY; LOW DRUG DOSE; MERKEL CELL TUMOR; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVERALL SURVIVAL; PNEUMONIA; PROTEIN EXPRESSION; REVIEW; SURVIVAL TIME; SYSTEMIC THERAPY; TREATMENT PLANNING;

EID: 84901245655     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers6021180     Document Type: Review

References (77)

1. Tang, C.K.; Toker, C. Trabecular carcinoma of the skin: An ultrastructural study. Cancer 1978, 42, 2311-2321.
2. De Wolff-Peeters, C.; Marien, K.; Mebis, J.; Desmet, V. A cutaneous APUDoma or Merkel cell tumor? A morphologically recognizable tumor with a biological and histological malignant aspect in contrast with its clinical behavior. Cancer 1980, 46, 1810-1816.
3. Feng, H.; Shuda, M.; Chang, Y.; Moore, P.S. Clonal integration of a polyomavirus in human merkel cell carcinoma. Science 2008, 319, 1096-1100.
4. Heath, M.; Jaimes, N.; Lemos, B.; Mostaghimi, A.; Wang, L.C.; Peñas, P.F.; Nghiem, P. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: The AEIOU features. J. Am. Acad. Dermatol. 2008, 58, 375-381.
5. Lemos, B.D.; Storer, B.E.; Iyer, J.G.; Phillips, J.L; Bichakjian, C.K.; Fang, L.C.; Johnson, T.M.; Liegeois-Kwon, N.J.; Otley, C.C.; Paulson, K.G. et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging system. J. Am. Acad. Dermatol. 2010, 63, 751-761.
6. Santamaria-Barria, J.A.; Boland, G.M.; Yeap, B.Y.; Nardi, V.; Dias-Santagata, D.; Cusack, J.C., Jr. Merkel cell carcinoma: 30-year experience from a single institution. Ann. Surg. Oncol. 2013, 20, 1365-1373.
7. Voog, E.; Biron, P.; Martin, J.P.; Blay, J.Y. Chemotherapy for patients with locally advanced or metastatic merkel cell carcinoma. Cancer 1999, 85, 2589-2595.
8. Tai, P.T.; Yu, E.; Winquist, E.; Hammond, A.; Stiff, L.; Tonita, J.; Gilchrist, J. Chemotherapy in neuroendocrine/merkel cell carcinoma of the skin: Case series and review of 204 cases. J. Clin. Oncol. 2000, 18, 2493-2499.
9. Engels, E.A.; Frisch, M.; Goedert, J.J.; Biggar, R.J.; Miller, R.W. Merkel cell carcinoma and HIV infection. Lancet 2002, 359, 497-498.
10. Rodig, S.J.; Cheng, J.; Wardzala, J.; DoRosario, A.; Scanlon, J.J.; Laga, A.C.; Martinez-Fernandez, A.; Barletta, J.A.; Bellizzi, A.M.; Sadasivam, S. et al. Improved detection suggests all merkel cell carcinomas harbor merkel polyomavirus. J. Clin. Invest. 2012, 122, 4645-4653.
11. Dunn, G.P.; Bruce, A.T.; Ikeda, H.; Old, L.J.; Schreiber, R.D. Cancer immunoediting: From immunosurveillance to tumor escape. Nat. Immunol. 2002, 3, 991-998.
12. Kroemer, G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat. Med. 1997, 3, 614-620.
13. Moll, I.; Gillardon, F.; Waltering, S.; Schmelz, M.; Moll, R. Differences of bcl-2 protein expression between Merkel cells and Merkel cell carcinomas. J. Cutan. Pathol. 1996, 23, 109-117.
14. Schlagqbauer-Wadl, H.; Klosner, G.; Heere-Ress, E.; Waltering, S.; Moll, I.; Wolff, K.; Pehamberger, H.; Jansen, B. Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice. J. Invest. Dermatol. 2000, 114, 725-730.
15. Shah, M.H.; Varker, K.A.; Collamore, M.; Zwiebel, J.A.; Coit, D.; Kelsen, D.; Chung, K.Y. G3139 (Genasense) in patients with advanced merkel cell carcinoma. Am. J. Clin. Oncol. 2009, 32, 174-179.
16. Sahi, H.; Koljonen, V.; Kavola, H.; Haglund, C.; Tukiainen, E.; Sihto, H.; Böhling, T. Bcl-2 expression indicates better prognosis of merkel cell carcinoma regardless of the presence of merkel cell polyomavirus. Virchows Arch. 2012, 461, 553-559.
17. Lasithiotaki, I.; Antoniou, K.M.; Derdas, S.P.; Sarchianaki, E.; Symvoulakis, E.K.; Psaraki, A.; Spandidos, D.A.; Stathopoulos, E.N.; Siafakas, N.M.; Sourvinos, G. The presence of merkel cell polyomavirus is associated with deregulated expression of BRAF and Bcl-2 genes in non-small cell lung cancer. Int. J. Cancer 2013, 133, 604-612.
18. Kartha, R.V.; Sundram, U.N. Silent mutations in KIT and PDGFRA and coexpression of receptors with SCF and PDGFA in Merkel cell carcinoma: Implications for tyrosine kinase-based tumorigenesis. Mod. Pathol. 2008, 21, 96-104.
19. Krasagakis, K.; Krüger-Krasagakis, S.; Eberle, J.; Tsatsakis, A.; Tosca, A.D.; Stathopoulos, E.N. Co-expression of KIT receptor and its ligand stem cell factor in Merkel cell carcinoma. Dermatology 2009, 218, 37-43.
20. Krasagakis, K.; Fragiadaki, I.; Metaxari, M.; Krüger-Krasagakis, S.; Tzanakakis, G.N.; Stathopoulos, E.N.; Eberle, J.; Tavernarakis, N.; Tosca, A.D. Kit receptor activation by autocrine and paracrine stem cell factor stimulated growth of merkel cell carcinoma in vitro. J. Cell. Physiol. 2011, 226, 1099-1109
21. Feinmesser, M.; Halpern, M.; Kaganovsky, E.; Brenner, B.; Fenig, E.; Hodak, E.; Sulkes, J.; Okon, E. c-Kit expression in primary and metastatic merkel cell carcinoma. Am. J. Dermatopathol. 2004, 26, 458-462.
22. Samlowski, W.E.; Moon, J.; Tuthill, R.J.; Heinrich, M.C.; Balzer-Haas, N.S.; Merl, S.A.; DeConti, R.C.; Thompson, J.A.; Witter, M.T.; Flaherty, L.E. et al. A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331). Am. J. Clin. Oncol. 2010, 33, 495-499.
23. Swick, B.L.; Ravdel, L.; Fitzpatrick, J.E.; Robinson, W.A. Merkel cell carcinoma: Evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene- Implications for treatment with imatinib mesylate. J. Cutan. Pathol. 2007, 34, 324-329.
24. Loader, D.E.; Feldmann, R.; Baumgartner, M.; Breier, F.; Schrama, D.; Becker, J.C.; Steiner, A. Clinical remission of merkel cell carcinoma after treatment with imatinib. J. Am. Acad. Dermatol. 2013, 69, e181-e183.
25. Murray, R.D.; Kim, K.; Ren, S.G.; Chelly, M.; Umehara, Y.; Melmed, S. Central and peripheral actions of somatostatin on the growth hormone-IGF-1 axis. J. Clin. Invest. 2004, 114, 349-356.
26. Resmini, E.; Dadati, P.; Ravetti, J.L.; Zona, G.; Spaziante, R.; Saveanu, A.; Jaquet, P.; Culler, M.D.; Bianchi, F.; Rebora, A. et al. Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patients. J. Clin. Endocrinol. Metab. 2007, 92, 1592-1599.
27. Pyronet, S.; Bousquet, C.; Najib, S.; Azar, R.; Laklai, H.; Susini, C. Antitumor effects of somatostatin. Mol. Cell. Endocrinol. 2008, 286, 230-237.
28. Fougner, S.L.; Borota, O.C.; Berg, J.P.; Hald, J.K.; Ramm-Pettersen, J.; Bollerslev, J. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin. Endocrinol. 2008, 68, 458-465.
29. Papotti, M.; Macri, L.; Pagani, A.; Aloi, F.; Bussolati, G. Quantitation of somatostatin receptor type 2 in neuroendocrine (Merkel cell) carcinoma of the skin by competitive RT-PCR. Endocr. Pathol. 1999, 10, 37-46.
30. Fakiha, M.; Letertre, P.; Vuillez, J.P.; Lebeau, J. Remission of merkel cell tumor after somatostatin analog treatment. J. Cancer Res. Ther. 2010, 6, 382-384.
31. Cirillo, F.; Filippini, L.; Lima, G.F.; Caresana, G.; Alquati, P. Merkel cell tumor. Report of case and treatment with octreotide (abstract). Minerva Chir. 1997, 52, 1359-1365.
32. Takeuchi, H.; Morton, D.L.; Elashoff, D.; Hoon, D.S. Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. Int. J. Cancer. 2005, 117, 1032-1038.
33. O'Connor, D.S.; Schechner, J.S.; Adida, C.; Mesri, M.; Rothermel, A.L; Nath, A.K.; Pober, J.S.; Altieri, D.C. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am. J. Pathol. 2000, 156, 393-398.
34. Kim, J.; Mcniff, J.M. Nuclear expression of survivin portends a poor prognosis in merkel cell carcinoma. Mod. Pathol. 2008, 6, 764-769.
35. nrb complex, which is required for survivin expression. Biochem. Biophys. Res. Commun. 2012, 425, 711-716.
36. Arora, R.; Shuda, M.; Guastafierro, A.; Feng, H.; Toptan, T.; Tolstov, Y.; Normolle, D.; Vollmer, L.L.; Vogt, A.; Dömling, A. et al. Survivin is a therapeutic target in merkel cell carcinoma. Sci. Transl. Med. 2012, 4, doi:10.1126/scitranslmed.3003713.
37. Dresang, L.R.; Guastafierro, A.; Arora, R.; Yuri, M.; Yokota, H.; Naitou, M.; Takeuchi, M.; Yamanaka, K.; Kita, A.; Nakahara, T. et al. Response of merkel cell polyomavirus-positive merkel cell carcinoma xenografts to a surviving inhibitor. PLoS One 2013, 8, e80543.
38. Carter, P.J.; Senter, P.D. Antibody-drug conjugates for cancer therapy. Cancer J. 2008, 14, 154-169.
39. Kurokawa, M.; Nabeshima, K.; Akiyama, Y.; Maeda, S.; Nishida, T.; Nakayama, F.; Amano, M.; Ogata, K.; Setoyama, M. CD56: A useful marker for diagnosis merkel cell carcinoma. J. Dermatol. Sci. 2003, 31, 219-224.
40. Woll, P.J.; Moore, K.N.; Bhatia, S.; Fossella, F.V.; Chen, L.C.; O'Brien, M.; Lorigan, P.; Weitman, S.D.; O'Leary, J.J.; Zildjian, S. et al. Efficacy results from a phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors. J. Clin. Oncol. 2011, 29, Abstract No. e20511.
41. Laplante, M.; Sabatini, D.M. mTOR signaling in growth control and disease. Cell 2012, 149, 274-293.
42. Lin, Z.; McDermott, A.; Shao, L.; Kannan, A.; Morgan, M.; Stack, B.C., Jr.; Moreno, M.; Davis, D.A.; Cornelius, L.A.; Gao, L. Chronic mTOR activation promotes cell survival in merkel cell carcinoma. Cancer Lett. 2014, 344, 272-281.
43. Nardi, V.; Song, Y.; Santamaria-Barria, J.A.; Cosper, A.K.; Lam, Q.; Faber, A.C.; Boland, G.M.; Yeap, B.Y.; Bergethon, K.; Scialabba, V.L. et al. Activation of PI3K signaling in merkel cell carcinoma. Clin. Cancer Res. 2012, 18, 1227-1236.
44. Kukko, H.; Koljonen, V.; Lassus, P.; Tukiainen, E.; Haglund, C.; Böhling, T. Expression of vascular endothelial growth factor receptor-2 in Merkel cell carcinoma. Anticancer Res. 2007, 27, 2587-2589.
45. Fernandez-Figueras, M.T.; Puig, L.; Musulen, E.; Gilaberte, M.; Lerma, E.; Serrano, S.; Ferrandiz, C.; Ariza, A. Expression profiles associated with aggressive behavior in Merkel cell carcinoma. Mod. Pathol. 2007, 20, 90-101.
46. Davids, M.S.; Charlton, A.; Ng, S.S.; Chong, M.L.; Laubscher, K.; Dar, M.; Hodge, J.; Soong, R.; Goh, B.C. Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic merkel cell carcinoma. J. Clin. Oncol. 2009, 27, e97-e100.
47. Swick, B.L.; Ravdel, L.; Fitzpatrick, J.E.; Robinson, W.A. Platelet-derived growth factor receptor alpha mutational status and immunohistochemical expression in merkel cell carcinoma: Implications for treatment with imatininb mesylate. J. Cutan. Pathol. 2008, 35, 197-202.
48. Elisei, R.; Schlumberger, M.J.; Müller, S.P.; Schöffski, P.; Brose, M.S.; Shah, M.H.; Licitra, L.; Jarzab, B.; Medvedev, V.; Kreissl, M.C. et al. Cabozantinib in progressive medullary thyroid cancer. J. Clin. Oncol. 2013, 29, 3639-3646.
49. Dong, H.Y.; Liu, W.; Cohen, P.; Mahle, C.E.; Zhang, W. B-cell specific activation protein by the PAX-5 gene is commonly expressed in merkel cell carcinoma and small cell carcinomas. Am. J. Surg. Pathol. 2005, 29, 687-692.
50. Sennino, B.; Ishiguro-Oonuma, T.; Wei, Y.; Naylor, R.M.; Williamson, C.W.; Bhagwandin, V.; Tabruyn, S.P.; You, W.K.; Chapman, H.A.; Christensen, J.G. et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-MET and VEGF in pancreatic neuroendocrine tumors. Cancer Discov. 2012, 2, 270-287.
51. Korman, A.J.; Peggs, K.S.; Allison, J.P. Checkpoint blockade in cancer immunotherapy. Adv. Immunol. 2006, 90, 297-339.
52. + T cells. Immunity 1997, 7, 885-895.
53. Hodi, F.S.; O'Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363, 711-723.
54. Kayashima, K.; Ono, T.; Johno, M.; Kojo, Y.; Yamashita, N.; Matsunaga, W. Spontaneous regression in merkel cell (neuroendocrine) carcinoma of the skin. Arch. Dermatol. 1991, 127, 550-553.
55. Takenaka, H.; Kishimoto, S.; Shibagaki, R.; Nagata, M.; Yasumo, H. Merkel cell carcinoma with partial spontaneous regression-An immunohistochemical, ultrastructural, and TUNEL labeling study. Am. J. Dermatopathol. 1997, 19, 614-618.
56. Paulson, K.G.; Iyer, J.G.; Blom, A.; Warton, E.M.; Sokil, M.; Yelistratova, L.; Schuman, L.; Nagase, K.; Bhatia, S.; Asgari, M.M. et al. Systemic immune suppression as a stage-independent predictor of diminished Merkel cell carcinoma-specific survival. J. Invest. Dermatol. 2012, 133, 642-646.
57. + lymphocyte invasion as an independent predictor of survival. J. Clin. Oncol. 2011, 29, 1539-1546.
58. Keir, M.E.; Butte, M.J.; Freeman, G.J.; Sharpe, A.H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26, 677-704.
59. Messal, N.; Serriari, N.E.; Pastor, S.; Nunes, J.A.; Olive, D. PD-L2 is expressed on activated human T cells and regulates their function. Mol. Immunol. 2011, 48, 2214-2219.
60. Barber, D.L.; Wherry, E.J.; Masopust, D.; Zhu, B.; Allison, J.P.; Sharpe, A.H.; Freeman, G.J.; Ahmed, R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439, 682-687.
61. Ahmadzadeh, M.; Johnson, L.A.; Heemskerk, B.; Wunderlich, J.R.; Dudley, M.E.; White, D.E.; Rosenberg, S.A. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009, 114, 1537-1544.
62. Dong, H.; Strome, S.E.; Salomao, D.R.; Tamura, H.; Hirano, H.; Files, D.B.; Roche, P.C.; Lu, J.; Zhu, G.; Tamada, K. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat. Med. 2002, 8, 793-800.
63. Taube, J.M.; Anders, R.A.; Young, G.D.; Xu, H.; Sharma, R.; McMiller, T.L.; Chen, S.; Klein, A.P.; Pardoll, D.M.; Topalian, S.L. et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 2012, 4, doi:10.1126/scitranslmed.3003689.
64. Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B. et al. Safety, activity and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366, 2443-2454.
65. Afanasiev, O.K.; Yelistratova, L.; Miller, N.; Nagase, K.; Paulson, K.; Iyer, J.G.; Ibrani, D.; Koelle, D.M.; Nghiem, P. Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin. Cancer Res. 2013, 19, 5351-5360.
66. Lipson, E.J.; Vincent, J.G.; Loyo, M.; Kagohara, L.T.; Luber, B.S.; Wang, H.; Xu, H.; Nayar, S.K.; Wang, T.S.; Sidransky, D. et al. PD-L1 expression in the merkel cell carcinoma microenvironment: Association with inflammation, merkel cell polyomavirus, and overall survival. Cancer Immunol. Res. 2013, 1, 54-63.
67. Rosenberg, S.A.; Yang, J.C.; Sherry, R.M.; Kammula, U.S.; Hughes, M.S.; Phan, G.Q.; Citrin, D.E.; Restifo, N.P.; Robbins, P.F.; Wunderlich, J.R. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 2011, 17, 4550-4557.
68. Straathof, K.C.M.; Bollard, C.M.; Popat, U.; Huls, M.H.; Lopez, T.; Morriss, M.C.; Gresik, M.V.; Gee, A.P.; Russell, H.V.; Brenner, M.K. et al. Treatment of nasopharyngeal carcinoma with Epstein-barr virus-specific T lymphocytes. Blood 2005, 105, 1898-1904.
69. Lyngaa, R.; Pedersen, N.W.; Schrama, D.; Thrue, C.A.; Ibrani, D.; Met, O.; Thor Straten, P.; Nghiem, P.; Becker, J.C.; Hadrup, S.R. T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors. Clin. Cancer Res. 2014, 20, 1768-1778.
70. Daud, A.I.; DeConti, R.C.; Andrews, S.; Urbas, P.; Riker, A.I.; Sondak, V.K.; Munster, P.N.; Sullivan, D.M.; Ugen, K.E.; Messina, J.L. et al. Phase 1 trial of interleukin-12 plasmid electrocorporation in patients with metastatic melanoma. J. Clin. Oncol. 2008, 26, 5896-5903.
71. Marlind, J.; Kaspar, M.; Trachsel, E.; Sommavilla, R.; Hindle, S.; Bacci, C.; Giovannoni, L.; Neri, D. Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin. Cancer Res. 2008, 14, 6515-6524.
72. Orend, G.; Chiquet-Ehrismann, R. Tenascin-C induced signaling in cancer. Cancer Lett. 2006, 244, 143-163.
73. Pedretti, M.; Verpelli, C.; Marlind, J.; Bertani, G.; Sala, C.; Neri, D.; Bello, L. Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma. Br. J. Cancer 2010, 103, 827-836.
74. Schreibelt, G.; Tel, J.; Sliepen, K.H.; Benitez-Ribas, D.; Figdor, C.G.; Adema, G.J.; de Vries, I.J. Toll-like receptor expression and function in human dendritic cell subsets: Implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol. Immunother. 2010, 59, 1573-1582.
75. Trevejo, J.M.; Marino, M.W.; Philpott, N.; Josien, R.; Richards, E.C.; Elkon, K.B.; Falck-Pedersen, E. TNF-alpha-dependent maturation of local dendritic cells is critical for activating the adaptive immune response to virus infection. Proc. Natl. Acad. Sci. USA 2001, 98, 12162-12167.
76. Trinchieri, G. Interleukin-12: A cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994, 84, 4008-4027.
77. Behzad, H.; Huckriede, A.L.; Haynes, L.; Gentleman, B.; Coyle, K.; Wilschut, J.C.; Kollman, T.R.; Reed, S.G.; McElhaney, J.E. GLA-SE, a synthetic toll-like receptor 4 agonist, enhances t-cell responses to influenza vaccine in older adults. J. Infect. Dis. 2012, 205, 466-473.